Hereditary breast cancer; Genetic penetrance and current status with BRCA

The most important cause of developing hereditary breast cancer is germline mutations occurring in breast cancer (BCs) susceptibility genes, for example, BRCA1, BRCA2, TP53, CHEK2, PTEN, ATM, and PPM1D. Many BC susceptibility genes can be grouped into two classes, high‐ and low‐penetrance genes, eac...

Full description

Saved in:
Bibliographic Details
Published inJournal of cellular physiology Vol. 234; no. 5; pp. 5741 - 5750
Main Authors Mahdavi, Morteza, Nassiri, Mohammadreza, Kooshyar, Mohammad Mahdi, Vakili‐Azghandi, Masoume, Avan, Amir, Sandry, Ryan, Pillai, Suja, Lam, Alfred King‐yin, Gopalan, Vinod
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.05.2019
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The most important cause of developing hereditary breast cancer is germline mutations occurring in breast cancer (BCs) susceptibility genes, for example, BRCA1, BRCA2, TP53, CHEK2, PTEN, ATM, and PPM1D. Many BC susceptibility genes can be grouped into two classes, high‐ and low‐penetrance genes, each of which interact with multiple genes and environmental factors. However, the penetrance of genes can also be represented by a spectrum, which ranges between high and low. Two of the most common susceptibility genes are BRCA1 and BRCA2, which perform vital cellular functions for repair of homologous DNA. Loss of heterozygosity accompanied by hereditary mutations in BRCA1 or BRCA2 increases chromosomal instability and the likelihood of cancer, as well as playing a key role in stimulating malignant transformation. With regard to pathological features, familial breast cancers caused by BRCA1 mutations usually differ from those caused by BRCA2 mutations and nonfamilial BCs. It is essential to acquire an understanding of these pathological features along with the genetic history of the patient to offer an individualized treatment. Germline mutations in BRCA1 and BRCA2 genes are the main genetic and inherited factors for breast and ovarian cancer. In fact, these mutations are very important in developing early onset and increasing the risk of familial breast and ovarian cancer and responsible for 90% of hereditary BC cases. Therefore, according to the conducted studies, screening of BRCA1 and BRCA2 genes is recommended as an important marker for early detection of all patients with breast or ovarian cancer risk with family history of the disease. In this review, we summarize the role of hereditary genes, mainly BRCA1 and BRCA2, in BC.
AbstractList The most important cause of developing hereditary breast cancer is germline mutations occurring in breast cancer (BCs) susceptibility genes, for example, BRCA1, BRCA2, TP53, CHEK2, PTEN, ATM, and PPM1D. Many BC susceptibility genes can be grouped into two classes, high- and low-penetrance genes, each of which interact with multiple genes and environmental factors. However, the penetrance of genes can also be represented by a spectrum, which ranges between high and low. Two of the most common susceptibility genes are BRCA1 and BRCA2, which perform vital cellular functions for repair of homologous DNA. Loss of heterozygosity accompanied by hereditary mutations in BRCA1 or BRCA2 increases chromosomal instability and the likelihood of cancer, as well as playing a key role in stimulating malignant transformation. With regard to pathological features, familial breast cancers caused by BRCA1 mutations usually differ from those caused by BRCA2 mutations and nonfamilial BCs. It is essential to acquire an understanding of these pathological features along with the genetic history of the patient to offer an individualized treatment. Germline mutations in BRCA1 and BRCA2 genes are the main genetic and inherited factors for breast and ovarian cancer. In fact, these mutations are very important in developing early onset and increasing the risk of familial breast and ovarian cancer and responsible for 90% of hereditary BC cases. Therefore, according to the conducted studies, screening of BRCA1 and BRCA2 genes is recommended as an important marker for early detection of all patients with breast or ovarian cancer risk with family history of the disease. In this review, we summarize the role of hereditary genes, mainly BRCA1 and BRCA2, in BC.
The most important cause of developing hereditary breast cancer is germline mutations occurring in breast cancer (BCs) susceptibility genes, for example, BRCA1, BRCA2, TP53, CHEK2, PTEN, ATM, and PPM1D. Many BC susceptibility genes can be grouped into two classes, high- and low-penetrance genes, each of which interact with multiple genes and environmental factors. However, the penetrance of genes can also be represented by a spectrum, which ranges between high and low. Two of the most common susceptibility genes are BRCA1 and BRCA2, which perform vital cellular functions for repair of homologous DNA. Loss of heterozygosity accompanied by hereditary mutations in BRCA1 or BRCA2 increases chromosomal instability and the likelihood of cancer, as well as playing a key role in stimulating malignant transformation. With regard to pathological features, familial breast cancers caused by BRCA1 mutations usually differ from those caused by BRCA2 mutations and nonfamilial BCs. It is essential to acquire an understanding of these pathological features along with the genetic history of the patient to offer an individualized treatment. Germline mutations in BRCA1 and BRCA2 genes are the main genetic and inherited factors for breast and ovarian cancer. In fact, these mutations are very important in developing early onset and increasing the risk of familial breast and ovarian cancer and responsible for 90% of hereditary BC cases. Therefore, according to the conducted studies, screening of BRCA1 and BRCA2 genes is recommended as an important marker for early detection of all patients with breast or ovarian cancer risk with family history of the disease. In this review, we summarize the role of hereditary genes, mainly BRCA1 and BRCA2, in BC.The most important cause of developing hereditary breast cancer is germline mutations occurring in breast cancer (BCs) susceptibility genes, for example, BRCA1, BRCA2, TP53, CHEK2, PTEN, ATM, and PPM1D. Many BC susceptibility genes can be grouped into two classes, high- and low-penetrance genes, each of which interact with multiple genes and environmental factors. However, the penetrance of genes can also be represented by a spectrum, which ranges between high and low. Two of the most common susceptibility genes are BRCA1 and BRCA2, which perform vital cellular functions for repair of homologous DNA. Loss of heterozygosity accompanied by hereditary mutations in BRCA1 or BRCA2 increases chromosomal instability and the likelihood of cancer, as well as playing a key role in stimulating malignant transformation. With regard to pathological features, familial breast cancers caused by BRCA1 mutations usually differ from those caused by BRCA2 mutations and nonfamilial BCs. It is essential to acquire an understanding of these pathological features along with the genetic history of the patient to offer an individualized treatment. Germline mutations in BRCA1 and BRCA2 genes are the main genetic and inherited factors for breast and ovarian cancer. In fact, these mutations are very important in developing early onset and increasing the risk of familial breast and ovarian cancer and responsible for 90% of hereditary BC cases. Therefore, according to the conducted studies, screening of BRCA1 and BRCA2 genes is recommended as an important marker for early detection of all patients with breast or ovarian cancer risk with family history of the disease. In this review, we summarize the role of hereditary genes, mainly BRCA1 and BRCA2, in BC.
Author Sandry, Ryan
Lam, Alfred King‐yin
Mahdavi, Morteza
Gopalan, Vinod
Pillai, Suja
Nassiri, Mohammadreza
Kooshyar, Mohammad Mahdi
Vakili‐Azghandi, Masoume
Avan, Amir
Author_xml – sequence: 1
  givenname: Morteza
  surname: Mahdavi
  fullname: Mahdavi, Morteza
  organization: Institute of Biotechnology, Ferdowsi University of Mashhad
– sequence: 2
  givenname: Mohammadreza
  orcidid: 0000-0001-7119-8155
  surname: Nassiri
  fullname: Nassiri, Mohammadreza
  email: nassiryr@um.ac.ir
  organization: Institute of Biotechnology, Ferdowsi University of Mashhad
– sequence: 3
  givenname: Mohammad Mahdi
  surname: Kooshyar
  fullname: Kooshyar, Mohammad Mahdi
  organization: Mashhad University of Medical Sciences
– sequence: 4
  givenname: Masoume
  orcidid: 0000-0003-1169-9147
  surname: Vakili‐Azghandi
  fullname: Vakili‐Azghandi, Masoume
  organization: Institute of Biotechnology, Ferdowsi University of Mashhad
– sequence: 5
  givenname: Amir
  orcidid: 0000-0002-4968-0962
  surname: Avan
  fullname: Avan, Amir
  organization: School of Medicine, Griffith University
– sequence: 6
  givenname: Ryan
  surname: Sandry
  fullname: Sandry, Ryan
  organization: Faculty of Medicine, Mashhad University of Medical Sciences
– sequence: 7
  givenname: Suja
  surname: Pillai
  fullname: Pillai, Suja
  organization: School of Biomedical Sciences, Faculty of Medicine, The University of Queensland
– sequence: 8
  givenname: Alfred King‐yin
  orcidid: 0000-0003-2771-564X
  surname: Lam
  fullname: Lam, Alfred King‐yin
  organization: School of Medicine, Griffith University
– sequence: 9
  givenname: Vinod
  orcidid: 0000-0003-0366-9482
  surname: Gopalan
  fullname: Gopalan, Vinod
  organization: Faculty of Medicine, Mashhad University of Medical Sciences
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30552672$$D View this record in MEDLINE/PubMed
BookMark eNp90UFLwzAUB_Agis7pwS8gAS966JY0TdLiaQ51iqCInkuavGJHl84kZezbmzn1IOjpwcvvPcL_HaJd21lA6ISSESUkHc_1cpTKTGQ7aEBJIZNM8HQXDeIbTQqe0QN06P2cEFIUjO2jA0Y4T4VMB-huBg5ME5Rb48qB8gFrZTW4S3wLFkKj8XJT3aaJlTVY986BDdgHFXqPV014w1fP08kR2qtV6-H4qw7R6831y3SWPDze3k0nD4lmnGUJ5bmpDSdAjMlpIY2QJBW8rhgwKVkms0oTyZlQTEeU6ywX1NSMSZVDTSs2ROfbvUvXvffgQ7lovIa2VRa63pcp5VIIkTMR6dkvOu96Z-PvohJFKnJJZFSnX6qvFmDKpWsWMY7yO6QILrZAu857B_UPoaTcHKCMByg_DxDt-JfVMdzQdDZG2LT_TayaFtZ_ry7vp0_biQ_xWZQJ
CitedBy_id crossref_primary_10_1016_j_clbc_2024_01_001
crossref_primary_10_1016_j_isci_2023_108333
crossref_primary_10_1016_j_prp_2024_155318
crossref_primary_10_56050_01205498_2315
crossref_primary_10_3390_women1010002
crossref_primary_10_1113_JP284421
crossref_primary_10_1007_s00432_023_04663_9
crossref_primary_10_1186_s40659_024_00579_x
crossref_primary_10_1002_mgg3_1359
crossref_primary_10_1007_s11051_024_06153_6
crossref_primary_10_1097_MS9_0000000000002293
crossref_primary_10_3390_ijms252312585
crossref_primary_10_1016_j_bios_2021_113767
crossref_primary_10_3389_fcell_2020_00160
crossref_primary_10_18097_PBMCR1495
crossref_primary_10_1016_j_jaccao_2019_09_008
crossref_primary_10_1111_ahg_12592
crossref_primary_10_18632_aging_202315
crossref_primary_10_1016_j_biopha_2020_109956
crossref_primary_10_1051_e3sconf_202130802022
crossref_primary_10_1242_dmm_050211
crossref_primary_10_1007_s11033_022_07571_2
crossref_primary_10_1186_s13148_020_00888_4
crossref_primary_10_55489_njcm_130920222120
crossref_primary_10_1002_med_22058
crossref_primary_10_1007_s00268_023_07033_1
crossref_primary_10_1186_s12905_022_01732_y
crossref_primary_10_2196_38399
crossref_primary_10_1186_s12935_023_02972_0
crossref_primary_10_3831_KPI_2021_24_1_1
crossref_primary_10_1111_jcmm_14830
crossref_primary_10_1016_j_ijso_2023_100602
crossref_primary_10_3389_fonc_2022_963364
crossref_primary_10_5468_ogs_24054
crossref_primary_10_1186_s12916_022_02489_9
crossref_primary_10_5041_RMMJ_10522
crossref_primary_10_1097_MD_0000000000036905
crossref_primary_10_3343_alm_2020_40_2_114
crossref_primary_10_1016_j_clbc_2022_05_010
crossref_primary_10_1016_j_amjsurg_2024_116005
crossref_primary_10_3389_fonc_2023_1146008
crossref_primary_10_2147_CMAR_S348529
crossref_primary_10_1007_s10549_024_07503_7
crossref_primary_10_12998_wjcc_v9_i12_2923
crossref_primary_10_1186_s12935_025_03663_8
crossref_primary_10_1016_j_ejso_2022_02_019
crossref_primary_10_1016_j_jacr_2023_04_002
crossref_primary_10_3390_life12040524
crossref_primary_10_1111_jcmm_16907
crossref_primary_10_17116_profmed20192203126
crossref_primary_10_1007_s10911_022_09522_w
crossref_primary_10_1007_s11033_023_08458_6
crossref_primary_10_1016_j_breast_2023_103602
crossref_primary_10_1038_s41598_021_98737_8
crossref_primary_10_1016_j_ijbiomac_2023_126989
crossref_primary_10_1021_acsmaterialslett_3c00965
crossref_primary_10_1186_s12885_023_10822_5
crossref_primary_10_3390_ijms20122962
crossref_primary_10_1158_1940_6207_CAPR_21_0141
crossref_primary_10_1007_s12687_021_00570_z
crossref_primary_10_1038_s41523_022_00443_9
crossref_primary_10_3390_futurepharmacol5010004
crossref_primary_10_3390_cancers13163956
crossref_primary_10_1515_jbcpp_2019_0191
crossref_primary_10_7759_cureus_62160
crossref_primary_10_1177_03000605231223426
crossref_primary_10_1186_s40364_020_00223_2
crossref_primary_10_32635_2176_9745_RBC_2022v68n4_3083
crossref_primary_10_1016_j_tig_2022_11_002
crossref_primary_10_3390_cancers16234022
crossref_primary_10_1002_cam4_70632
crossref_primary_10_1016_j_mrfmmm_2022_111778
crossref_primary_10_3390_ijms25116221
crossref_primary_10_1080_00224499_2022_2144991
crossref_primary_10_1016_j_chphi_2023_100291
crossref_primary_10_1186_s12951_020_00613_6
crossref_primary_10_1016_j_beha_2020_101191
crossref_primary_10_1007_s10549_021_06292_7
crossref_primary_10_1109_TCBB_2020_3027392
crossref_primary_10_1002_jmv_26198
crossref_primary_10_1016_j_jconrel_2022_06_050
crossref_primary_10_1016_j_breast_2021_02_001
crossref_primary_10_3389_fgene_2022_982930
crossref_primary_10_1016_j_hpr_2024_300764
crossref_primary_10_1007_s11033_022_08198_z
crossref_primary_10_3892_ije_2021_4
crossref_primary_10_1245_s10434_024_15793_w
Cites_doi 10.1016/j.celrep.2014.12.044
10.1186/1471-2407-8-155
10.1186/bcr419
10.1002/(SICI)1098-2264(200002)27:2<130::AID-GCC3>3.0.CO;2-U
10.1007/s12282-012-0432-4
10.1007/s13238-010-0010-5
10.1073/pnas.0800441105
10.7314/APJCP.2013.14.7.4339
10.1038/nature05887
10.1126/science.2270482
10.1001/jama.286.18.2251
10.1200/JCO.2006.09.1066
10.1002/cncr.11310
10.1038/onc.2011.408
10.1158/0008-5472.CAN-03-2970
10.1038/ng1902
10.1186/s12885-015-1934-1
10.1038/87876
10.1126/science.8091231
10.1073/pnas.1706392114
10.1073/pnas.85.9.3044
10.1038/ng1096-185
10.1146/annurev.ge.28.120194.002303
10.1097/PAS.0b013e31826cabbd
10.7326/0003-4819-143-5-200509060-00012
10.1002/ijc.29210
10.1200/JCO.2008.20.5179
10.1007/s11033-011-0958-0
10.1038/onc.2016.502
10.1038/nature03445
10.1371/journal.pgen.1002101
10.1515/BC.2002.030
10.1136/jcp.2005.032151
10.1093/carcin/bgq069
10.1038/82533
10.1158/0008-5472.CAN-08-1569
10.1111/cge.12037
10.1158/0008-5472.CAN-10-1907
10.1002/cncr.24200
10.1200/JCO.2004.05.055
10.1016/j.dnarep.2015.03.002
10.1093/jnci/90.7.484
10.1002/humu.10154
10.1086/375033
10.1038/ng0197-14
10.1086/301903
10.3892/ol.2011.390
10.1056/NEJM198705213162101
10.1007/s10552-007-0118-y
10.1002/humu.20169
10.1016/j.ejmg.2017.07.016
10.1097/01.pas.0000213428.61374.06
10.1016/S0065-2660(08)00601-9
10.1007/s10689-012-9581-z
10.1023/B:JOMG.0000048770.90334.3b
10.1038/sj.bjc.6600008
10.1056/NEJMra0802968
10.1056/NEJMoa031759
ContentType Journal Article
Copyright 2018 Wiley Periodicals, Inc.
2019 Wiley Periodicals, Inc.
Copyright_xml – notice: 2018 Wiley Periodicals, Inc.
– notice: 2019 Wiley Periodicals, Inc.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7TK
7U7
8FD
C1K
FR3
K9.
P64
RC3
7X8
DOI 10.1002/jcp.27464
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Neurosciences Abstracts
Toxicology Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Genetics Abstracts
Technology Research Database
Toxicology Abstracts
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList MEDLINE

Genetics Abstracts
MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Biology
EISSN 1097-4652
EndPage 5750
ExternalDocumentID 30552672
10_1002_jcp_27464
JCP27464
Genre reviewArticle
Journal Article
Review
GroupedDBID ---
-DZ
-~X
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
36B
3O-
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5GY
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
85S
8UM
930
9M8
A03
AAESR
AAEVG
AAHHS
AAHQN
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDPE
ABEFU
ABEML
ABIJN
ABJNI
ABPPZ
ABPVW
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACNCT
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AIAGR
AITYG
AIURR
AIWBW
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AUFTA
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMNLL
BMXJE
BNHUX
BQCPF
BROTX
BRXPI
BY8
CS3
D-E
D-F
DCZOG
DPXWK
DR1
DR2
DRFUL
DRSTM
DU5
EBD
EBS
EJD
EMB
EMOBN
F00
F01
F04
F5P
FEDTE
G-S
G.N
GNP
GODZA
H.T
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
H~9
IH2
IX1
J0M
JPC
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M56
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MVM
MXFUL
MXSTM
N04
N05
N9A
NEJ
NF~
NNB
O66
O9-
OHT
OIG
P2P
P2W
P2X
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
ROL
RWI
RWR
RX1
RYL
S10
SAMSI
SUPJJ
SV3
TN5
TWZ
UB1
UPT
V2E
V8K
VQP
W8V
W99
WBKPD
WH7
WIB
WIH
WIK
WJL
WNSPC
WOHZO
WQJ
WRC
WXSBR
WYB
WYISQ
X7M
XG1
XJT
XOL
XPP
XSW
XV2
Y6R
YQT
YZZ
ZGI
ZXP
ZZTAW
~IA
~WT
AAYXX
ADXHL
AETEA
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
PKN
7TK
7U7
8FD
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
C1K
FR3
K9.
P64
RC3
7X8
ID FETCH-LOGICAL-c3534-158dfd50e0dd8197d670265fb3e3773474bc07536a3c0e08c4861df337a8ef1b3
IEDL.DBID DR2
ISSN 0021-9541
1097-4652
IngestDate Fri Jul 11 04:08:28 EDT 2025
Sat Jul 12 04:12:25 EDT 2025
Wed Feb 19 02:31:15 EST 2025
Thu Apr 24 23:06:33 EDT 2025
Tue Jul 01 04:56:52 EDT 2025
Wed Jan 22 17:09:43 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords BRCA
breast cancer
germline mutations
hereditary genes
Language English
License 2018 Wiley Periodicals, Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3534-158dfd50e0dd8197d670265fb3e3773474bc07536a3c0e08c4861df337a8ef1b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0003-0366-9482
0000-0001-7119-8155
0000-0002-4968-0962
0000-0003-1169-9147
0000-0003-2771-564X
PMID 30552672
PQID 2169268707
PQPubID 1006363
PageCount 10
ParticipantIDs proquest_miscellaneous_2157666836
proquest_journals_2169268707
pubmed_primary_30552672
crossref_primary_10_1002_jcp_27464
crossref_citationtrail_10_1002_jcp_27464
wiley_primary_10_1002_jcp_27464_JCP27464
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate May 2019
2019-05-00
20190501
PublicationDateYYYYMMDD 2019-05-01
PublicationDate_xml – month: 05
  year: 2019
  text: May 2019
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle Journal of cellular physiology
PublicationTitleAlternate J Cell Physiol
PublicationYear 2019
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References e_1_2_6_1_53_1
e_1_2_6_1_6_1
e_1_2_6_1_55_1
e_1_2_6_1_8_1
e_1_2_6_1_11_1
e_1_2_6_1_34_1
e_1_2_6_1_2_1
e_1_2_6_1_32_1
e_1_2_6_1_4_1
Phillips K. A. (e_1_2_6_1_51_1) 2000; 18
e_1_2_6_1_27_1
e_1_2_6_1_25_1
e_1_2_6_1_46_1
e_1_2_6_1_29_1
e_1_2_6_1_48_1
e_1_2_6_1_43_1
e_1_2_6_1_45_1
e_1_2_6_1_22_1
e_1_2_6_1_60_1
e_1_2_6_1_20_1
e_1_2_6_1_41_1
e_1_2_6_1_62_1
e_1_2_6_1_15_1
e_1_2_6_1_13_1
e_1_2_6_1_36_1
e_1_2_6_1_57_1
e_1_2_6_1_19_1
e_1_2_6_1_17_1
e_1_2_6_1_59_1
e_1_2_6_1_7_1
e_1_2_6_1_54_1
e_1_2_6_1_9_1
e_1_2_6_1_56_1
e_1_2_6_1_3_1
e_1_2_6_1_12_1
e_1_2_6_1_33_1
e_1_2_6_1_50_1
e_1_2_6_1_5_1
e_1_2_6_1_10_1
e_1_2_6_1_31_1
e_1_2_6_1_52_1
Yoshida K. (e_1_2_6_1_64_1) 2004; 95
Lynch H. T. (e_1_2_6_1_38_1) 1971; 133
e_1_2_6_1_26_1
Murphy C. G. (e_1_2_6_1_42_1) 2010; 24
e_1_2_6_1_24_1
e_1_2_6_1_47_1
e_1_2_6_1_28_1
e_1_2_6_1_49_1
e_1_2_6_1_44_1
e_1_2_6_1_23_1
e_1_2_6_1_61_1
e_1_2_6_1_21_1
e_1_2_6_1_40_1
e_1_2_6_1_63_1
Johannesdottir G. (e_1_2_6_1_30_1) 1996; 56
e_1_2_6_1_16_1
e_1_2_6_1_37_1
e_1_2_6_1_14_1
e_1_2_6_1_35_1
e_1_2_6_1_58_1
e_1_2_6_1_18_1
e_1_2_6_1_39_1
References_xml – ident: e_1_2_6_1_35_1
  doi: 10.1016/j.celrep.2014.12.044
– ident: e_1_2_6_1_15_1
  doi: 10.1186/1471-2407-8-155
– ident: e_1_2_6_1_5_1
  doi: 10.1186/bcr419
– ident: e_1_2_6_1_11_1
  doi: 10.1002/(SICI)1098-2264(200002)27:2<130::AID-GCC3>3.0.CO;2-U
– ident: e_1_2_6_1_47_1
  doi: 10.1007/s12282-012-0432-4
– ident: e_1_2_6_1_63_1
  doi: 10.1007/s13238-010-0010-5
– ident: e_1_2_6_1_25_1
  doi: 10.1073/pnas.0800441105
– ident: e_1_2_6_1_33_1
  doi: 10.7314/APJCP.2013.14.7.4339
– ident: e_1_2_6_1_13_1
  doi: 10.1038/nature05887
– ident: e_1_2_6_1_27_1
  doi: 10.1126/science.2270482
– ident: e_1_2_6_1_32_1
  doi: 10.1001/jama.286.18.2251
– ident: e_1_2_6_1_10_1
  doi: 10.1200/JCO.2006.09.1066
– ident: e_1_2_6_1_8_1
  doi: 10.1002/cncr.11310
– ident: e_1_2_6_1_16_1
  doi: 10.1038/onc.2011.408
– ident: e_1_2_6_1_22_1
  doi: 10.1158/0008-5472.CAN-03-2970
– ident: e_1_2_6_1_54_1
  doi: 10.1038/ng1902
– ident: e_1_2_6_1_14_1
  doi: 10.1186/s12885-015-1934-1
– ident: e_1_2_6_1_43_1
  doi: 10.1038/87876
– volume: 133
  start-page: 644
  year: 1971
  ident: e_1_2_6_1_38_1
  article-title: Carcinoma of the breast and ovary in three families
  publication-title: Surgery, Gynecology and Obstetrics
– ident: e_1_2_6_1_62_1
  doi: 10.1126/science.8091231
– ident: e_1_2_6_1_9_1
  doi: 10.1073/pnas.1706392114
– ident: e_1_2_6_1_46_1
  doi: 10.1073/pnas.85.9.3044
– ident: e_1_2_6_1_53_1
  doi: 10.1038/ng1096-185
– ident: e_1_2_6_1_39_1
  doi: 10.1146/annurev.ge.28.120194.002303
– ident: e_1_2_6_1_24_1
  doi: 10.1097/PAS.0b013e31826cabbd
– volume: 56
  start-page: 3663
  issue: 16
  year: 1996
  ident: e_1_2_6_1_30_1
  article-title: High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients
  publication-title: Cancer Research
– ident: e_1_2_6_1_44_1
  doi: 10.7326/0003-4819-143-5-200509060-00012
– ident: e_1_2_6_1_18_1
  doi: 10.1002/ijc.29210
– ident: e_1_2_6_1_59_1
  doi: 10.1200/JCO.2008.20.5179
– ident: e_1_2_6_1_60_1
  doi: 10.1007/s11033-011-0958-0
– ident: e_1_2_6_1_19_1
  doi: 10.1038/onc.2016.502
– ident: e_1_2_6_1_17_1
  doi: 10.1038/nature03445
– ident: e_1_2_6_1_7_1
  doi: 10.1371/journal.pgen.1002101
– ident: e_1_2_6_1_61_1
  doi: 10.1515/BC.2002.030
– ident: e_1_2_6_1_26_1
  doi: 10.1136/jcp.2005.032151
– ident: e_1_2_6_1_48_1
  doi: 10.1093/carcin/bgq069
– ident: e_1_2_6_1_50_1
  doi: 10.1038/82533
– ident: e_1_2_6_1_6_1
  doi: 10.1158/0008-5472.CAN-08-1569
– ident: e_1_2_6_1_55_1
  doi: 10.1111/cge.12037
– ident: e_1_2_6_1_3_1
  doi: 10.1158/0008-5472.CAN-10-1907
– ident: e_1_2_6_1_28_1
  doi: 10.1002/cncr.24200
– ident: e_1_2_6_1_36_1
  doi: 10.1200/JCO.2004.05.055
– ident: e_1_2_6_1_23_1
  doi: 10.1016/j.dnarep.2015.03.002
– ident: e_1_2_6_1_31_1
  doi: 10.1093/jnci/90.7.484
– ident: e_1_2_6_1_37_1
  doi: 10.1002/humu.10154
– volume: 95
  start-page: 866
  issue: 11
  year: 2004
  ident: e_1_2_6_1_64_1
  article-title: Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage
  publication-title: Cancer Prevention Research
– ident: e_1_2_6_1_2_1
  doi: 10.1086/375033
– ident: e_1_2_6_1_52_1
  doi: 10.1038/ng0197-14
– ident: e_1_2_6_1_20_1
  doi: 10.1086/301903
– volume: 24
  start-page: 410
  issue: 5
  year: 2010
  ident: e_1_2_6_1_42_1
  article-title: HER2‐positive breast cancer: Beyond trastuzumab
  publication-title: Oncology
– ident: e_1_2_6_1_12_1
  doi: 10.3892/ol.2011.390
– ident: e_1_2_6_1_56_1
  doi: 10.1056/NEJM198705213162101
– ident: e_1_2_6_1_29_1
  doi: 10.1007/s10552-007-0118-y
– ident: e_1_2_6_1_40_1
  doi: 10.1002/humu.20169
– ident: e_1_2_6_1_58_1
  doi: 10.1016/j.ejmg.2017.07.016
– ident: e_1_2_6_1_41_1
  doi: 10.1097/01.pas.0000213428.61374.06
– ident: e_1_2_6_1_49_1
  doi: 10.1016/S0065-2660(08)00601-9
– volume: 18
  start-page: 107S
  year: 2000
  ident: e_1_2_6_1_51_1
  article-title: Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers
  publication-title: Journal of Clinical Oncology
– ident: e_1_2_6_1_45_1
  doi: 10.1007/s10689-012-9581-z
– ident: e_1_2_6_1_57_1
  doi: 10.1023/B:JOMG.0000048770.90334.3b
– ident: e_1_2_6_1_4_1
  doi: 10.1038/sj.bjc.6600008
– ident: e_1_2_6_1_21_1
  doi: 10.1056/NEJMra0802968
– ident: e_1_2_6_1_34_1
  doi: 10.1056/NEJMoa031759
SSID ssj0009933
Score 2.588477
SecondaryResourceType review_article
Snippet The most important cause of developing hereditary breast cancer is germline mutations occurring in breast cancer (BCs) susceptibility genes, for example,...
The most important cause of developing hereditary breast cancer is germline mutations occurring in breast cancer (BCs) susceptibility genes, for example, BRCA1...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 5741
SubjectTerms Animals
Biomarkers, Tumor - genetics
BRCA
BRCA1 protein
BRCA1 Protein - genetics
BRCA2 protein
BRCA2 Protein - genetics
Breast cancer
Breast Neoplasms - genetics
Cancer
Deoxyribonucleic acid
DNA
DNA repair
Environmental factors
Female
Genes
Genetic Predisposition to Disease
Genetic transformation
Genetics
Genomic instability
germline mutations
Health risk assessment
Health risks
hereditary genes
Heredity
Heterozygosity
Homology
Humans
Loss of Heterozygosity
Mutation
Ovarian cancer
p53 Protein
Patients
Pedigree
Penetrance
PTEN protein
Risk Assessment
Risk Factors
Stability
Title Hereditary breast cancer; Genetic penetrance and current status with BRCA
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcp.27464
https://www.ncbi.nlm.nih.gov/pubmed/30552672
https://www.proquest.com/docview/2169268707
https://www.proquest.com/docview/2157666836
Volume 234
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS9xAEB9EKPTFWq321JZtKaUvOZPsZ_DpeihXoaVIBR-EkP0ItGo8vNyD_vXu7CYRWwulTwlkkt3szuz-Znf2NwAfTG2dzao00cK5hFWcJoWqioRRY3hua-Eknkb--k3MTtnxGT9bgYP-LEzkhxgW3NAywniNBl7pxf4DaegvMx97l0ogFyjGaiEgOnmgjiq6NPIhBIGzrGcVSvP94c3Hc9EfAPMxXg0TztELOO-rGuNMLsbLVo_N3W8sjv_5L-uw1gFRMoma8xJWXLMBm5PGO-FXt-QjCaGhYc19A57FjJW3m_Blhrk9f7a-KKIxnr0lBvXm5oAggbX_FpnjFdN1OFI1lphIAEXw5NJyQXDdl3w-mU5ewenR4Y_pLOmyMSSGcsqSjCtbW5661FoPI6QV0vtvvNbUUSkpk0wbjz-oqKjxQsowJTJbUyor5epM0y1Yba4b9xpIyo3XB869a6OZUUY5Kqz3pBSXrhYqH8Gnvl9K01GVY8aMyzKSLOelb7AyNNgI3g-i88jP8ZTQXt-5ZWeiizLPRJELP1zJEbwbHnvjwh2TqnHXS5Tx7pgQiooRbEelGEpBqrRcSKxs6Nq_F18eT7-Hm51_F92F5x6aFTG0cg9W25ule-PhT6vfBj2_B4oN_mc
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9RAEJ8gxuiLCqicgCzGGF96tN3PRl6Oi-T4jCGQ8EKadnebqFgu0HvAv56d3bYElcT41Caddre7M9v5TWd_A_BBV8aapIijUlgbsYLTKFNFFjGqNU9NJazE3ciHR2JyyvbO-NkcbHV7YQI_RB9wQ8vw6zUaOAakN-9YQ7_r6dBhKsEewWOs6O0B1fEdeVTWFpL3SQicJR2vUJxu9rfe_xr94WLe91j9J2fnBZx3nQ2ZJj-Gs6Yc6l-_8Tj-79u8hOetL0pGQXkWYM7Wi7A0qh0O_3lDPhKfHerD7ovwJBStvFmC3QmW9_zWuLZIiSntDdGoOlefCXJYu2eRKR6xYoclRW2IDhxQBDcvza4Jhn7J9vF49ApOd76cjCdRW5Ah0pRTFiVcmcrw2MbGOE9CGiEdhONVSS2VkjLJSu1cECoKqp2Q0kyJxFSUykLZKinpa5ivL2u7DCTm2qkE5w7dlEwrrSwVxoEpxaWthEoH8KmbmFy3bOVYNOMiDzzLae4GLPcDNoD3veg0UHT8TWi1m928tdLrPE1Elgq3YskBbPSXnX3hT5OitpczlHGITAhFxQDeBK3oW0G2tFRI7Kyf24ebz_fGX_3J238XXYenk5PDg_xg92h_BZ45Ty0LmZarMN9czeya84aa8p1X-ltwtgKR
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB5RKioutEAf29LWVFXVS5YkfkactktXC7QIoSJxQIoS25GAElaQPdBf37GdBNGHVPWUSJnEjj1jf2OPvwF4rytjTVLEUSmsjVjBaZSpIosY1ZqnphJWutPIXw_E9JjtnfCTBdjuzsIEfoh-wc1Zhh-vnYHPTLV1Rxp6rmdDdKkEewAPmYiVU-mdozvuqKzNI-9jEDhLOlqhON3qX70_Gf2GMO8DVj_jTB7DaVfXEGhyMZw35VD_-IXG8T9_5gmstEiUjILqrMKCrddgfVSjF355Sz4QHxvqF93XYCmkrLxdh92pS-551mBRpHQB7Q3RTnGut4ljsMZvkZm7unwdlhS1ITowQBF3dGl-Q9zCL_l0NB49hePJ52_jadSmY4g05ZRFCVemMjy2sTGII6QREh04XpXUUikpk6zUCECoKKhGIaWZEompKJWFslVS0mewWF_V9gWQmGtUCM7RtymZVlpZKgy6UopLWwmVDuBj1y-5brnKXcqM73lgWU5zbLDcN9gA3vWis0DQ8Sehja5z89ZGb_I0EVkqcLySA9jsH6N1uS2TorZXcyeD_pgQiooBPA9K0ZfiuNJSIV1lfdf-vfh8b3zob17-u-hbeHS4M8m_7B7sv4JlhGlZCLPcgMXmem5fIxRqyjde5X8Cf6YBSQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hereditary+breast+cancer%3B+Genetic+penetrance+and+current+status+with+BRCA&rft.jtitle=Journal+of+cellular+physiology&rft.au=Mahdavi%2C+Morteza&rft.au=Nassiri%2C+Mohammadreza&rft.au=Kooshyar%2C+Mohammad+Mahdi&rft.au=Vakili-Azghandi%2C+Masoume&rft.date=2019-05-01&rft.eissn=1097-4652&rft.volume=234&rft.issue=5&rft.spage=5741&rft_id=info:doi/10.1002%2Fjcp.27464&rft_id=info%3Apmid%2F30552672&rft.externalDocID=30552672
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9541&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9541&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9541&client=summon